β-d-Ribofuranose As a Core with a Phosphodiester Moiety As the Enzyme Recognition Site for Codrug Development

Overview

Journal Org Lett

Publisher American Chemical Society

Specialties Biochemistry
Chemistry

Date 2024 Nov 14

PMID 39540692

Authors

Jih Ru Hwu

Avijit Panja

Shwu-Chen Tsay

Wen-Chieh Huang

Shu-Yu Lin

Chen-Sheng Yeh

Wu-Chou Su

Li-Xing Yang

Dar-Bin Shieh

Affiliations

Soon will be listed here.

Abstract

An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and carbonate groups as linking joints, a phosphodiester moiety as an enzyme recognition site, and lenalidomide and paclitaxel as the constituent drugs. The codrug synthesis involves seven steps with a 33% overall yield. The target codrug increases its water solubility 685 times versus paclitaxel.

References

Ezrahi S, Aserin A, Garti N . Basic principles of drug delivery systems - the case of paclitaxel. Adv Colloid Interface Sci. 2018; 263:95-130. DOI: 10.1016/j.cis.2018.11.004. View

Amraoui K, Belhadj K, Maitre B, Janniere-Nartey C, Dupuis J . Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients. Eur Respir Rev. 2013; 22(127):93-5. PMC: 9487425. DOI: 10.1183/09059180.00001912. View

Meng Z, Lv Q, Lu J, Yao H, Lv X, Jiang F . Prodrug Strategies for Paclitaxel. Int J Mol Sci. 2016; 17(5). PMC: 4881612. DOI: 10.3390/ijms17050796. View

Chen Y, Armstrong Z, Artola M, Florea B, Kuo C, de Boer C . Activity-Based Protein Profiling of Retaining α-Amylases in Complex Biological Samples. J Am Chem Soc. 2021; 143(5):2423-2432. PMC: 7883350. DOI: 10.1021/jacs.0c13059. View

Das N, Dhanawat M, Dash B, Nagarwal R, Shrivastava S . Codrug: an efficient approach for drug optimization. Eur J Pharm Sci. 2010; 41(5):571-88. DOI: 10.1016/j.ejps.2010.09.014. View

Yu H, Yang H, Shi E, Tang W . Development and Clinical Application of Phosphorus-Containing Drugs. Med Drug Discov. 2020; 8:100063. PMC: 7445155. DOI: 10.1016/j.medidd.2020.100063. View

Szabo Z, Foroughbakhshfasaei M, Gal R, Horvath P, Komjati B, Noszal B . Chiral separation of lenalidomide by liquid chromatography on polysaccharide-type stationary phases and by capillary electrophoresis using cyclodextrin selectors. J Sep Sci. 2017; 41(6):1414-1423. DOI: 10.1002/jssc.201701211. View

Aljuffali I, Lin C, Chen C, Fang J . The codrug approach for facilitating drug delivery and bioactivity. Expert Opin Drug Deliv. 2016; 13(9):1311-25. DOI: 10.1080/17425247.2016.1187598. View

Muller G, Chen R, Huang S, Corral L, Wong L, Patterson R . Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999; 9(11):1625-30. DOI: 10.1016/s0960-894x(99)00250-4. View

10.

Hakimelahi G, Moosavi-Movahedi A, Sadeghi M, Tsay S, Hwu J . Design, synthesis, and structure-activity relationship of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses. J Med Chem. 1995; 38(23):4648-59. DOI: 10.1021/jm00023a004. View

11.

Alzoman N . A Validated Stability-Indicating and Stereoselective HPLC Method for the Determination of Lenalidomide Enantiomers in Bulk Form and Capsules. J Chromatogr Sci. 2016; 54(5):730-5. PMC: 4890444. DOI: 10.1093/chromsci/bmv247. View

12.

Jacques V, Czarnik A, Judge T, Van der Ploeg L, DeWitt S . Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs. Proc Natl Acad Sci U S A. 2015; 112(12):E1471-9. PMC: 4378388. DOI: 10.1073/pnas.1417832112. View

13.

Shigematsu M, Kawamura T, Kirino Y . Generation of 2',3'-Cyclic Phosphate-Containing RNAs as a Hidden Layer of the Transcriptome. Front Genet. 2018; 9:562. PMC: 6277466. DOI: 10.3389/fgene.2018.00562. View

14.

Pradere U, Garnier-Amblard E, Coats S, Amblard F, Schinazi R . Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev. 2014; 114(18):9154-218. PMC: 4173794. DOI: 10.1021/cr5002035. View

15.

Wei Y, Pu X, Zhao L . Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review). Oncol Rep. 2017; 37(6):3159-3166. DOI: 10.3892/or.2017.5593. View

16.

Richardson P, Mitsiades C, Hideshima T, Anderson K . Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006; 6(8):1165-73. DOI: 10.1586/14737140.6.8.1165. View

17.

Cavalli A, Bolognesi M, Minarini A, Rosini M, Tumiatti V, Recanatini M . Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008; 51(3):347-72. DOI: 10.1021/jm7009364. View

18.

Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T . Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010; 4:215-45. PMC: 2899783. DOI: 10.2147/ce.s6002. View

19.

Marupudi N, Han J, Li K, Renard V, Tyler B, Brem H . Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007; 6(5):609-21. DOI: 10.1517/14740338.6.5.609. View

20.

Bergstrom C, Wassvik C, Johansson K, Hubatsch I . Poorly soluble marketed drugs display solvation limited solubility. J Med Chem. 2007; 50(23):5858-62. DOI: 10.1021/jm0706416. View